Zacks Research Has Negative Forecast for BHC Q1 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Equities researchers at Zacks Research lowered their Q1 2025 EPS estimates for Bausch Health Companies in a research note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will earn $0.80 per share for the quarter, down from their previous estimate of $0.87. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.27 EPS, FY2025 earnings at $4.26 EPS, Q2 2026 earnings at $1.10 EPS and Q3 2026 earnings at $1.28 EPS.

Several other equities research analysts have also recently issued reports on the stock. Royal Bank of Canada decreased their price objective on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Bausch Health Companies has an average rating of “Hold” and an average price target of $7.42.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at $7.15 on Friday. The company has a market cap of $2.63 billion, a P/E ratio of -59.54, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59. The firm has a 50-day simple moving average of $7.21 and a two-hundred day simple moving average of $7.65. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%.

Institutional Trading of Bausch Health Companies

Several institutional investors and hedge funds have recently modified their holdings of BHC. Mountain Hill Investment Partners Corp. acquired a new position in Bausch Health Companies during the fourth quarter worth approximately $56,000. Bank of Nova Scotia acquired a new stake in Bausch Health Companies during the 4th quarter valued at $83,000. One68 Global Capital LLC acquired a new stake in Bausch Health Companies during the 4th quarter valued at $90,000. Balyasny Asset Management L.P. bought a new position in Bausch Health Companies during the 4th quarter valued at $97,000. Finally, Alpine Global Management LLC bought a new position in Bausch Health Companies during the 4th quarter valued at $114,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.